

STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 115796

TO: Rei-Tsang Shiao
Location: 5a10 / 5c18
Wednesday, March 10, 2004
Art Unit: 1626
Phone: 272-0707
Serial Number: 09 / 766547

From: Jan Delaval
Location: Biotech-Chem Library
Rem 1A51
Phone: 272-2504

jan.delaval@uspto.gov

Search Notes

Scientific and Technical Information Center

Requester's Full Name: Robert (Randy) Shinn Examiner #: 79521 Date: 3/1/04
 An Unit: 1626 Phone Number: 2-0707 Serial Number: 09-7665147
 Mail Box and Bldg/Room Location: 5A10 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.


Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Thiazole, imidazole and pyrazole
 Inventors (please provide full names): Wigle et al


Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

I. search to Methods of use of cpd I or 2,



I.



R^a, R^b, R^c are sub

J is O, S.

R^c is O, alkyl, - , Ar,

NH-C(=O)-(CH₂)_n-D-R^eR^f

R^e is formula II

II search methods of use of the compounds of claim 6. for treating diabetes, kidney disease, hypertension, etc.

STAFF USE ONLY

Searcher: [Signature]
 Searcher Phone #: 22504
 Searcher Location: _____
 Date Searcher Provided: 3/1/04
 Date Completed: 3/1/04
 Searcher Prep & Review Time: _____

Type of Search

NA Sequence (#) _____
 AA Sequence (#) _____
 Structure (#) ☒ _____
 Bibliographic _____
 Litigation _____
 Fulltext _____

Vendors and cost where applicable

STN ☒ _____
 Dialog _____
 Quested Other: _____
 On-line _____
 Local News _____
 Sequence Systems _____

=> d his

(FILE 'HOME' ENTERED AT 13:37:31 ON 10 MAR 2004)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 13:38:00 ON 10 MAR 2004

L1 1 S US20020022622/PN
E WAGLE D/AU
L2 181 S E3-E7,E10-E12
E VASAN S/AU
L3 43 S E3-E9
E EGAN J/AU
L4 106 S E3,E11,E12
E EGAN JOHN/AU
L5 66 S E3,E9-E11
E ALTEON/PA,CS
L6 63 S E3-E10
L7 35 S L2-L5 AND L6
L8 17 S L7 AND HETER?/SC,SX
L9 1 S L1 AND L8
L10 16 S L8 NOT L9
SEL RN L9

FILE 'REGISTRY' ENTERED AT 13:40:22 ON 10 MAR 2004

L11 11 S E1-E11
L12 10 S L11 AND NR>=1
L13 2 S L12 AND (C19H14N2O2S OR C13H14N2O2S)

FILE 'HCAPLUS' ENTERED AT 13:43:54 ON 10 MAR 2004

SET SMARTSELECT ON
L14 SEL L10 1- RN : 447 TERMS
SET SMARTSELECT OFF

FILE 'REGISTRY' ENTERED AT 13:43:55 ON 10 MAR 2004

L15 447 S L14
L16 158 S L15 AND NCSC2/ES
L17 34 S L16 AND 1/NR
L18 1 S L17 AND CL/ELS
L19 33 S L17 NOT L18
L20 10 S L19 NOT IUM
L21 3 S L20 AND (C7H11NS OR C6H9NS OR C3H3NS)
L22 89 S L16 AND C6/ES
L23 10 S L22 NOT IUM
L24 1 S L23 AND F/ELS
L25 650 S NCSC2/ES AND 46.150.18/RID AND 2/NR AND 2/N AND 1/F AND 1/S A
L26 162 S L25 NOT O/ELS
L27 17 S L26 AND 9/C
L28 15 S L27 AND 4
L29 8 S L28 AND 4 FLUOROPHENYL
L30 5 S L29 NOT CL/ELS
SEL RN 1 5
L31 2 S E12-E13
L32 160825 S NCSC2-C6/ES
L33 2063 S L32 AND 2/NR AND 1/CL AND 1/NC
L34 862 S L33 AND 2/N
L35 196 S L34 NOT O/ELS
L36 114 S L35 AND 1/S
L37 102 S L36 NOT F/ELS
L38 21 S L37 AND 7/C
L39 5 S L38 AND 4 CHLORO
L40 2 S L39 AND 2
L41 1 S L40 NOT BR/ELS
L42 3991 S L32 AND C6-C6/ES

L43 388 S L42 AND DIMETHYL
L44 26 S L43 AND ONE
L45 18 S L44 AND 4/NR
L46 8 S L45 AND 2/N
L47 6 S L46 AND 1/NC
L48 5 S L47 AND 1/O
L49 2 S L48 AND 19/C
L50 1 S 109317-64-8
L51 0 S L43 AND TRIHYDRO
L52 4 S L42 AND TRIHYDRO
L53 1269 S L42 AND 4/NR
L54 107 S L53 AND L43
L55 52 S L54 AND 2/N
L56 47 S L55 NOT L48
L57 30 S L56 NOT IUM
L58 9 S L13,L21,L41,L31,L50
L59 3 S L30 NOT L31
L60 12 S L58,L59
SEL RN
L61 68 S E14-E25/CRN
L62 19 S L61 NOT (MXS/CI OR COMPD OR WITH)
L63 17 S L62 NOT PMS/CI
L64 16 S L63 NOT CONJUGATE

FILE 'HCAPLUS' ENTERED AT 14:36:18 ON 10 MAR 2004

L65 2744 S L60 OR L64
L66 5 S L1-L6 AND L65
L67 5 S L1,L66
E AGING/CT
L68 38222 S E3
L69 24980 S E19-E24
E E19+ALL
L70 33749 S E4,E5
L71 36458 S E3+NT
E E25+ALL
L72 4936 S E1
E E6+ALL
L73 67222 S E4,E3+NT
L74 5 S L65 AND L68-L73
SEL DN AN 1 3 5
L75 3 S E1-E9
L76 6 S L67,L75 AND L1-L10,L65-L75
L77 44 S (L60 OR L64) (L) THU/RL
L78 109 S (L60 OR L64) (L) (ADV OR BAC OR DMA OR PAC OR PKT)/RL
L79 398 S L65 AND (PHARMACEUT? OR PHARMACOL? OR PATHOL?)/SC,SX
L80 473 S L77-L79
L81 5 S L80 AND (AGING OR AGEING)
L82 4 S L81 NOT 30/SC
L83 6 S L76,L82

FILE 'REGISTRY' ENTERED AT 14:44:11 ON 10 MAR 2004

FILE 'HCAPLUS' ENTERED AT 14:45:32 ON 10 MAR 2004

FILE 'REGISTRY' ENTERED AT 14:45:37 ON 10 MAR 2004

SEL RN L60 7 8 9 12
L84 8 S L60 NOT E10-E13

FILE 'HCAPLUS' ENTERED AT 14:46:38 ON 10 MAR 2004

L85 34 S L84
L86 18 S L85 AND L80
L87 13 S L86 NOT ?FUNG?
L88 10 S L87 NOT L83

=> fil reg

FILE 'REGISTRY' ENTERED AT 14:48:17 ON 10 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 MAR 2004 HIGHEST RN 660815-69-0
DICTIONARY FILE UPDATES: 9 MAR 2004 HIGHEST RN 660815-69-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide can tot 160

L60 ANSWER 1 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 441285-73-0 REGISTRY
CN 2-Thiazolidinamine, N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C9 H11 F N2 S
SR CA
LC STN Files: CA, CAPLUS




from claim 6
page 50

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:93744

L60 ANSWER 2 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 302559-76-8 REGISTRY
CN Acetamide, 2-(3,5-dimethylphenoxy)-N-2-thiazolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide
FS 3D CONCORD
MF C13 H14 N2 O2 S
SR Chemical Library
LC STN Files: CA, CAPLUS, CHEMCATS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:93744

REFERENCE 2: 137:93743

REFERENCE 3: 135:122497

L60 ANSWER 3 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN

RN 289491-05-0 REGISTRY


CN 2-Furancarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C19 H14 N2 O2 S

SR Chemical Library

LC STN Files: CA, CAPLUS, CHEMCATS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:93744

REFERENCE 2: 137:93743

REFERENCE 3: 135:122497

L60 ANSWER 4 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN

RN 137935-26-3 REGISTRY


CN 4-Thiazolamine, N-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C9 H9 F N2 S

SR CA

LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 116:6459

L60 ANSWER 5 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 109317-64-8 REGISTRY
CN 7(4H)-Benzothiazolone, 5,6-dihydro-5,5-dimethyl-2-(2-naphthalenylamino)-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H18 N2 O S
CI COM
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS
(*File contains numerically searchable property data)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:93744

REFERENCE 2: 107:58918

L60 ANSWER 6 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 77815-14-6 REGISTRY
CN 2-Thiazolamine, 4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Amino-4-(4-fluorophenyl)thiazole
FS 3D CONCORD
MF C9 H7 F N2 S
CI COM
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX,
SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

21 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
22 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:149652
REFERENCE 2: 137:310439
REFERENCE 3: 133:252829
REFERENCE 4: 131:322593
REFERENCE 5: 131:139512
REFERENCE 6: 128:312900
REFERENCE 7: 127:5225
REFERENCE 8: 126:89392
REFERENCE 9: 122:105732
REFERENCE 10: 118:38821

L60 ANSWER 7 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN

RN 19952-47-7 REGISTRY

CN 2-Benzothiazolamine, 4-chloro- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzothiazole, 2-amino-4-chloro- (6CI, 8CI)

OTHER NAMES:

CN 2-Amino-4-chlorobenzothiazole

CN 4-Chloro-1,3-benzothiazol-2-ylamine

CN 4-Chloro-2-benzothiazolamine

FS 3D CONCORD

MF C7 H5 Cl N2 S


CI COM

LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT,
CHEMCATS, CHEMLIST, CSCHEM, HODOC*, IFICDB, IFIPAT, IFIUDB, RTECS*,
SPECINFO, TOXCENTER, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

146 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
146 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 140:111335
REFERENCE 2: 139:395854
REFERENCE 3: 139:133557
REFERENCE 4: 139:48450
REFERENCE 5: 139:32012
REFERENCE 6: 138:368620
REFERENCE 7: 138:99909
REFERENCE 8: 137:118555
REFERENCE 9: 137:93763
REFERENCE 10: 137:93744

L60 ANSWER 8 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN

RN 18640-74-9 REGISTRY

CN Thiazole, 2-(2-methylpropyl)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Thiazole, 2-isobutyl- (8CI)

OTHER NAMES:

CN 2-(2-Methylpropyl)thiazole

CN 2-Isobutyl-1,3-thiazole

CN 2-Isobutylthiazole

CN NSC 290430

FS 3D CONCORD


MF C7 H11 N S

CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHM, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


112 REFERENCES IN FILE CA (1907 TO DATE)

112 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:162588
REFERENCE 2: 140:127361
REFERENCE 3: 140:24222
REFERENCE 4: 139:364960
REFERENCE 5: 139:363842

REFERENCE 6: 139:349826
REFERENCE 7: 139:261206
REFERENCE 8: 139:229658
REFERENCE 9: 139:229546
REFERENCE 10: 139:51951

L60 ANSWER 9 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 13623-11-5 REGISTRY
CN Thiazole, trimethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thiazole, 2,4,5-trimethyl- (6CI, 7CI, 8CI)
OTHER NAMES:
CN 2,4,5-Trimethylthiazole
CN NSC 170614
CN Trimethylthiazole
FS 3D CONCORD
MF C6 H9 N S
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA,
CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSChem, IFICDB, IFIPAT,
IFIUDB, MEDLINE, NAPRALERT, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

149 REFERENCES IN FILE CA (1907 TO DATE)
149 REFERENCES IN FILE CAPLUS (1907 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:6779
REFERENCE 2: 138:401896
REFERENCE 3: 138:390526
REFERENCE 4: 137:93744
REFERENCE 5: 137:78191
REFERENCE 6: 137:14996
REFERENCE 7: 136:290698
REFERENCE 8: 136:246626
REFERENCE 9: 136:52910
REFERENCE 10: 135:150221

L60 ANSWER 10 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 774-50-5 REGISTRY
CN 2-Thiazolamine, 5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thiazole, 2-amino-5-(p-fluorophenyl)- (7CI, 8CI)
FS 3D CONCORD
MF C9 H7 F N2 S
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


REFERENCE 1: 101:54977

REFERENCE 2: 94:121514

REFERENCE 3: 92:128793

REFERENCE 4: 57:10831

L60 ANSWER 11 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 457-59-0 REGISTRY
CN 2-Thiazolamine, N-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Thiazoline, 2-(p-fluoroanilino)- (8CI)
FS 3D CONCORD
MF C9 H9 F N2 S
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CHEMCATS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:209215

REFERENCE 2: 134:162957

REFERENCE 3: 128:189475

L60 ANSWER 12 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN

RN 288-47-1 REGISTRY

CN Thiazole (6CI, 8CI, 9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C3 H3 N S

CI COM, RPS

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES,
DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*,
NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE,
TOXCENTER, TULSA, USPAT2, USPATFULL, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2365 REFERENCES IN FILE CA (1907 TO DATE)

415 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

2367 REFERENCES IN FILE CAPLUS (1907 TO DATE)

37 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 140:145601

REFERENCE 2: 140:136181

REFERENCE 3: 140:128286

REFERENCE 4: 140:111367

REFERENCE 5: 140:104451

REFERENCE 6: 140:97781

REFERENCE 7: 140:94092

REFERENCE 8: 140:93825

REFERENCE 9: 140:79851

REFERENCE 10: 140:42043

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 14:48:32 ON 10 MAR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Mar 2004 VOL 140 ISS 11

FILE LAST UPDATED: 9 Mar 2004 (20040309/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.



=> d all hitstr tot 183

L83 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:521496 HCAPLUS
DN 137:93744
ED Entered STN: 12 Jul 2002
TI Preparation of thiazole derivatives for the treatment of fibrotic diseases
IN Wagle, Dilip; Martin, Gail; Bell, Stanely C.; Lavoie, Edmond J.
PA Alteon, Inc., USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-541
ICS A61K031-5377; A61K031-496; A61K031-454; A61K031-421; A61K031-426
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053161	A1	20020711	WO 2001-US50822	20011228
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1353676	A1	20031022	EP 2001-991611	20011228
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2002183317	A1	20021205	US 2001-38116	20011231
	US 6596744	B2	20030722		
	US 2003225146	A1	20031204	US 2003-440896	20030519
PRAI	US 2000-259107P	P	20001229		
	US 2001-259239P	P	20010102		
	US 2001-296247P	P	20010606		
	WO 2001-US50822	W	20011228		
	US 2001-38116	A1	20011231		
OS	MARPAT 137:93744				

GI




- AB Provided is a method of decreasing intraocular pressure or improving ocular accommodation, comprising administration of I, II [J = O, S, NR'; Ra-b = H, acylamino, acyloxyalkyl, alkanoyl, alkenyl, alkoxy, etc.; R' = alkyl, alkenyl, H, Ar; Rc = oxo, H, alkyl, alkylthio, H, mercapto, amino, amino-alkyl, etc.]. For instance, 3,5-dimethylphenol was alkylated with bromoacetic acid (110°, 4 h) to yield (3,5-dimethylphenoxy)acetic acid which was coupled to 2-aminothiazole (CH₂Cl₂, EDCI, HOBT, NMM) to give 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide. The activity of example compds. in breaking, reversing or inhibiting the formation of advanced glycosylation end products (AGEs) or AGE-mediated cross-links was determined (no data).
- ST fibrotic disease thiazole prepn
- IT Fibrosis
Human
(preparation of thiazole derivs. for treatment of fibrotic diseases)
- IT 288-47-1P, Thiazole 13623-11-5P, 2,4,5-Trimethylthiazole
18640-74-9P, 2-Isobutylthiazole 19952-47-7P,
2-Amino-4-chlorobenzothiazole 109317-64-8P 181070-25-7P,
2,6-Diaminobenzothiazole dihydrochloride 289491-05-0P
302559-76-8P, 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide
441285-73-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of thiazole derivs. for treatment of fibrotic diseases)
- IT 73326-20-2P, 2-(2-Bromoacetamido)thiazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thiazole derivs. for treatment of fibrotic diseases)
- IT 79-08-3, Bromoacetic acid 88-14-2, 2-Furoic acid 92-36-4,
2-(4-Aminophenyl)-6-methylbenzothiazole 96-50-4, 2-Aminothiazole
108-68-9, 3,5-Dimethylphenol 527-69-5, 2-Furoyl chloride 598-21-0,
Bromoacetyl bromide 6285-57-0, 2-Amino-6-nitrobenzothiazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of thiazole derivs. for treatment of fibrotic diseases)
- RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE (1) Cerami; US 6007865 A 1999 HCAPLUS
(2) Wagle; US 6121300 A 2000 HCAPLUS
- IT 288-47-1P, Thiazole 13623-11-5P, 2,4,5-Trimethylthiazole
18640-74-9P, 2-Isobutylthiazole 19952-47-7P,
2-Amino-4-chlorobenzothiazole 109317-64-8P 289491-05-0P
302559-76-8P, 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide
441285-73-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of thiazole derivs. for treatment of fibrotic diseases)
- RN 288-47-1 HCAPLUS

CN Thiazole (6CI, 8CI, 9CI) (CA INDEX NAME)




RN 13623-11-5 HCAPLUS

CN Thiazole, trimethyl- (9CI) (CA INDEX NAME)




RN 18640-74-9 HCAPLUS

CN Thiazole, 2-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 19952-47-7 HCAPLUS

CN 2-Benzothiazolamine, 4-chloro- (9CI) (CA INDEX NAME)




RN 109317-64-8 HCAPLUS

CN 7(4H)-Benzothiazolone, 5,6-dihydro-5,5-dimethyl-2-(2-naphthalenylamino)- (9CI) (CA INDEX NAME)




RN 289491-05-0 HCAPLUS

CN 2-Furancarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 302559-76-8 HCAPLUS

CN Acetamide, 2-(3,5-dimethylphenoxy)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 441285-73-0 HCAPLUS

CN 2-Thiazolidinamine, N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



L83 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:521487 HCAPLUS

DN 137:93743

ED Entered STN: 12 Jul 2002

TI Preparation of thiazole derivatives as antiglaucoma agents

IN Wagle, Dilip; Gall, Martin; Bell, Stanley C.; Lavoie, Edmond J.

PA Alteon, Inc., USA

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-425



CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053156	A1	20020711	WO 2001-US49834	20011228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

EP 1359910 A1 20031112 EP 2001-988373 20011228
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2002119970 A1 20020829 US 2001-36856 20011231
 PRAI US 2000-259428P P 20001229
 US 2001-296258P P 20010606
 WO 2001-US49834 W 20011228
 OS MARPAT 137:93743
 GI



AB Provided is a method of decreasing intraocular pressure or improving ocular accommodation, comprising administration of I, II [J = O, S, NR'; Ra-b = H, acylamino, acyloxyalkyl, alkanoyl, alkenyl, alkoxy, etc.; R' = alkyl, alkenyl, H, Ar; Rc = oxo, H, alkyl, alkylthio, H, mercapto, amino, amino-alkyl, etc.]. For instance, 3,5-dimethylphenol was alkylated with bromoacetic acid (110°, 4 h) to yield (3,5-dimethylphenoxy)acetic acid which was coupled to 2-aminothiazole (CH₂Cl₂, EDCI, HOBt, NMM) to give 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide. The activity of example compds. in breaking, reversing or inhibiting the formation of advanced glycosylation end products (AGEs) or AGE-mediated cross-links was determined (no data).

ST glaucoma intraocular pressure accommodation thiazole prepn
 IT Antiglaucoma agents
 Glaucoma (disease)
 Human
 (preparation of thiazole derivs. as antiglaucoma agents)

IT 302559-76-8P, 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antiglaucoma agent; preparation of thiazole derivs. as antiglaucoma agents)

IT 181070-25-7P, 2,6-Diaminobenzothiazole dihydrochloride
 289491-05-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antiglaucoma agents; preparation of thiazole derivs. as antiglaucoma agents)


IT 9001-03-0, Carbonic anhydrase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor; preparation of thiazole derivs. as antiglaucoma agents)

IT 73326-20-2P, 2-(2-Bromoacetamido)thiazole
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of thiazole derivs. as antiglaucoma agents)


IT 79-08-3, Bromoacetic acid 88-14-2, 2-Furoic acid 92-36-4,
 2-(4-Aminophenyl)-6-methylbenzothiazole 96-50-4, 2-Aminothiazole
 108-68-9, 3,5-Dimethylphenol 527-69-5, 2-Furoyl chloride 598-21-0,
 Bromoacetyl bromide 6285-57-0, 2-Amino-6-nitrobenzothiazole
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of thiazole derivs. as antiglaucoma agents)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

(1) Thomspson; US 5718912 A 1998 HCAPLUS
 IT 302559-76-8P, 2-(3,5-Dimethylphenoxy)-N-(thiazol-2-yl)acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (antiglaucoma agent; preparation of thiazole derivs. as antiglaucoma agents)
 RN 302559-76-8 HCAPLUS
 CN Acetamide, 2-(3,5-dimethylphenoxy)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



IT 289491-05-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (antiglaucoma agents; preparation of thiazole derivs. as antiglaucoma
 agents)
 RN 289491-05-0 HCAPLUS
 CN 2-Furancarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]- (9CI) (CA
 INDEX NAME)




L83 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:545486 HCAPLUS
 DN 135:122497
 ED Entered STN: 27 Jul 2001
 TI Preparation of thiazole, imidazole, and oxazole compounds for treatment of
 disorders associated with protein aging.
 IN Wagle, Dilip; Vasan, Sara; Egan, John J.
 PA Alteon, Inc., USA
 SO PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC A61K031-42; A61K031-415; A61K031-425
 CC 28-7 (Heterocyclic Compounds (More Than One Hetero
 Atom))
 Section cross-reference(s): 1

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001052847	A1	20010726	WO 2001-US1799	20010119
	WO 2001052847	C1	20020926		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			
		CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,			

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 2001032864 A5 20010731 AU 2001-32864 20010119
 US 2002022622 A1 20020221 US 2001-766547 20010119 <--
 EP 1248615 A1 20021016 EP 2001-904934 20010119
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004501863 T2 20040122 JP 2001-552895 20010119
 US 2003225146 A1 20031204 US 2003-440896 20030519
 PRAI US 2000-176995P P 20000119
 US 2000-183274P P 20000217
 US 2000-259107P P 20001229
 US 2000-259291P P 20001229
 US 2001-259237P P 20010102
 US 2001-259239P P 20010102
 WO 2001-US1799 W 20010119
 US 2001-296247P P 20010606
 US 2001-38116 A1 20011231
 OS MARPAT 135:122497
 GI



- AB A method of treating diabetes, kidney damage, blood vessel damage, atherosclerosis, peripheral vascular disease, coronary heart disease, heart failure, hypertension, retinopathy, peripheral neuropathy, cataracts, arthritis, Alzheimer's disease, tissue damage caused by contact with reducing sugars, stroke, skin elasticity reduction, and of increasing red blood cell deformability comprises administration of title compds. [I; J = O, S, NR₄; R₁, R₂ = H, acylamino, acyloxyalkyl, alkanoyl, alkanoylalkyl, alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylamino, allyl, amino, etc.; R₁R₂ = atoms to form a fused (substituted) aryl, cycloalkyl, heterocyclyl, or heteroaryl ring; R₃ = O, H, alkyl, alkylthio, H, SH, amino, aminoalkyl, aminoaryl, etc.; R₄ = alkyl, alkenyl, H, aryl; n = 0, 1] (no data). Thus, 2-amino-6-nitrobenzothiazole was hydrogenated in MeOH over Pd/C at 60 psi for 6.5 h at room temperature to give 2,6-diaminobenzothiazole dihydrochloride.
- ST thiazole imidazole oxazole prepn protein **aging** inhibitor;
 diabetes treatment thiazole imidazole oxazole prep; kidney damage treatment thiazole imidazole oxazole prep; blood vessel damage treatment thiazole imidazole oxazole prep; atherosclerosis treatment thiazole imidazole oxazole prep; retinopathy treatment thiazole imidazole oxazole prep; arthritis treatment thiazole imidazole oxazole prep
- IT Antiarteriosclerotics
 (antiatherosclerotics; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Artery, disease
 (coronary, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)

- IT Erythrocyte
(deformability improvement; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Heart, disease
(failure, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Kidney, disease
(injury, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Nerve, disease
(peripheral neuropathy, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Blood vessel, disease
(peripheral, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Anti-Alzheimer's agents
Antiarthritics
Antidiabetic agents
Antihypertensives
(preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Carbohydrates, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(reducing sugars, treatment of tissue damage due to contact with reducing sugars; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Eye, disease
(retinopathy, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Brain, disease
(stroke, treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Proteins, general, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(treatment of **aging**; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Blood vessel
(treatment of blood vessel damage; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Diabetes mellitus
(treatment of complications; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT **Aging, animal**
(treatment of protein **aging**; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Skin
(treatment of skin elasticity reduction; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein **aging**)
- IT Animal tissue
(treatment of tissue damage due to contact with reducing sugars; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders

associated with protein aging)

IT Cataract

(treatment; preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein aging)

IT 5407-51-2P, 2,6-Diaminobenzothiazole 181070-25-7P 289491-05-0P 302559-76-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein aging)

IT 88-14-2, 2-Furoic acid 92-36-4, 2-(4-Aminophenyl)-6-methylbenzothiazole 96-50-4, 2-Aminothiazole 108-68-9, 3,5-Dimethylphenol 527-69-5, 2-Furoyl chloride 598-21-0, Bromoacetyl bromide 6285-57-0, 2-Amino-6-nitrobenzothiazole

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein aging)

IT 88-14-2, 2-Furoic acid 92-36-4, 2-(4-Aminophenyl)-6-methylbenzothiazole 96-50-4, 2-Aminothiazole 108-68-9, 3,5-Dimethylphenol 527-69-5, 2-Furoyl chloride 598-21-0, Bromoacetyl bromide 6285-57-0, 2-Amino-6-nitrobenzothiazole

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein aging)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Cerami; US 5853703 A 1998 HCAPLUS
- (2) Chatterjee; WO 9941220 A1 1999 HCAPLUS
- (3) Lai, C; WO 9966924 A1 1999 HCAPLUS


IT 289491-05-0P 302559-76-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazole, imidazole, and oxazole compds. for treatment of disorders associated with protein aging)


RN 289491-05-0 HCAPLUS

CN 2-Furancarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]- (9CI) (CA INDEX NAME)



RN 302559-76-8 HCAPLUS

CN Acetamide, 2-(3,5-dimethylphenoxy)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



L83 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:98234 HCAPLUS

DN 132:146649

ED Entered STN: 11 Feb 2000

TI Sulfonamide derivatives for potentiating glutamate receptor function, preparation thereof, pharmaceutical compositions, and therapeutic use

IN Arnold, Macklin Brian; Bleisch, Thomas John; Ornstein, Paul Leslie; Smith, Edward C.; Zarrinmayeh, Hamideh; Zimmerman, Dennis Michael

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 1-11 (Pharmacology)

Section cross-reference(s): 25, 27, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006083	A2	20000210	WO 1999-US17018	19990728
	WO 2000006083	A3	20000713		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2338994	AA	20000210	CA 1999-2338994	19990728
	AU 9952356	A1	20000221	AU 1999-52356	19990728
	US 6500865	B1	20021231	US 2001-744413	20010123
PRAI	US 1998-94970P	P	19980731		
	WO 1999-US17018	W	19990728		
OS	MARPAT 132:146649				
AB	The invention provides sulfonamide derivs. useful for potentiating glutamate receptor function in a mammal and therefore useful for treating a wide variety of conditions, e.g. psychiatric and neurol. disorders. Preparation of e.g. N-[4-(3-thienyl)-1-phenylethyl]-2-propanesulfonamide is described.				
ST	sulfonamide deriv prepn glutamate receptor therapeutic; propanesulfonamide deriv prepn glutamate receptor therapeutic; psychiatric neurol disorder sulfonamide deriv prepn				
IT	Aging, animal (age-related dementia and memory impairment; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)				
IT	Mental disorder (attention deficit disorder; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)				

- IT Mental disorder
(attention deficit hyperactivity disorder; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
(capsules; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
- IT Nervous system
(degeneration; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
- IT Mental disorder
(dementia, age-related; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
- IT Drugs
(drug-induced psychosis; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
- IT Mental disorder
(psychosis, cognitive deficit associated with; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
- IT Antidepressants
Antipsychotics
Cognition enhancers
Drug delivery systems
Movement disorders
Nervous system agents
(sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
- IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
- IT Drug delivery systems
(tablets; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
- IT 14062-25-0P, Ethyl 4-bromophenylacetate 73918-56-6P,
2-(4-Bromophenyl)ethylamine 131818-17-2P 133778-10-6P 211315-18-3P
211315-19-4P 211315-20-7P 256381-10-9P 257604-10-7P 257604-11-8P
257604-12-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
- IT 106-40-1, 4-Bromoaniline 124-63-0, Methanesulfonyl chloride
288-47-1, Thiazole 298-12-4, Glyoxylic acid 623-00-7,
4-Bromobenzonitrile 813-19-4, Bis(tributyltin) 1072-85-1,
2-Fluorobromobenzene 1562-34-1 1878-68-8, 4-Bromophenylacetic acid
5391-88-8 5419-55-6, Triisopropyl borate 6165-69-1,
Thiophene-3-boronic acid 10147-37-2, Isopropylsulfonyl chloride
22627-70-9, 3-Ethoxy-2-cyclopenten-1-one 24424-99-5, Di-tert-butyl dicarbonate
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
- IT 257604-08-3P 257604-09-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)
- IT 1765-93-1P, 4-Fluorobenzeneboronic acid 74213-24-4P, Dibromoformaldoxime
86108-58-9P, 2-Trimethylstannylthiazole 112080-39-4P 120157-97-3P

126747-14-6P, 4-Cyanophenylboronic acid 133778-14-0P 185399-96-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)

IT 288-47-1, Thiazole

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction; sulfonamide derivs. for potentiating glutamate receptor function, preparation, pharmaceutical compns., and therapeutic use)

RN 288-47-1 HCAPLUS

CN Thiazole (6CI, 8CI, 9CI) (CA INDEX NAME)



L83 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:25966 HCAPLUS

DN 130:100661

ED Entered STN: 13 Jan 1999

TI Thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts

IN Cerami, Anthony; Ulrich, Peter C.; Wagle, Dilip R.; Hwang, San-Bao; Vasan, Sara; Egan, John J.

PA The Picower Institute for Medical Research, USA; Alteon Inc.

SO U.S., 30 pp., Cont.-in-part of U.S. Ser. No. 473,104, abandoned.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K031-38

ICS C07D277-24

NCL 424053000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 17, 28, 62

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5853703	A	19981229	US 1996-588249	19960118
	US 5656261	A	19970812	US 1995-375155	19950118
	CA 2210684	AA	19960725	CA 1996-2210684	19960118
	WO 9622095	A2	19960725	WO 1996-US663	19960118
	WO 9622095	A3	19970227		
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9647599	A1	19960807	AU 1996-47599	19960118
	AU 714607	B2	20000106		
	EP 808163	A2	19971126	EP 1996-903540	19960118
	EP 808163	B1	20030723		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	CN 1185736	A	19980624	CN 1996-192393	19960118
	JP 10512864	T2	19981208	JP 1996-522379	19960118
	BR 9607598	A	19991130	BR 1996-7598	19960118
	EP 1327887	A2	20030716	EP 2003-75955	19960118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	AT 245420	E	20030815	AT 1996-903540	19960118
	PT 808163	T	20031231	PT 1996-96903540	19960118
	FI 9703031	A	19970915	FI 1997-3031	19970717

	NO 9703308	A	19970918	NO 1997-3308	19970717
	US 6007865	A	19991228	US 1997-971878	19971119
	US 38330	E	20031125	US 1999-373345	19990812
	US 6440749	B1	20020827	US 1999-470482	19991222
	US 2002192842	A1	20021219	US 2002-174883	20020619
	US 2004034074	A1	20040219	US 2003-418398	20030418
PRAI	US 1995-375155	A2	19950118		
	US 1995-473104	B2	19950607		
	US 1995-473184	A	19950607		
	EP 1996-903540	A3	19960118		
	US 1996-588249	A	19960118		
	WO 1996-US663	W	19960118		
	US 1997-971878	A3	19971119		
	US 1999-470482	A3	19991222		
	US 2002-174883	A1	20020619		
OS	MARPAT 130:100661				
AB	The present invention relates to compns. and methods for inhibiting and reversing nonenzymic crosslinking (protein aging). Accordingly, compns. are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which addnl. reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain agents useful are thiazolium salts. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymic crosslinking is also disclosed.				
ST	thiazolium deriv advanced glycosylation endproduct inhibitor; dentifrice thiazolium deriv advanced glycosylation endproduct inhibitor; food preservative thiazolium deriv advanced glycosylation endproduct inhibitor; aging inhibitor thiazolium deriv advanced glycosylation endproduct inhibitor				
IT	Glycoproteins, specific or class RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process) (AGE (advanced glycosylation end product); thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)				
IT	Immunoglobulins RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); BIOL (Biological study); OCCU (Occurrence); PROC (Process) (G, erythrocyte-linked, decrease of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)				
IT	Erythrocyte (IgG crosslinked to, decrease of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)				
IT	Proteins, general, biological studies RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (aging of, prevention of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)				
IT	Tooth (discoloration of, prevention of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)				
IT	Diabetes mellitus (glucose crosslinking in; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)				
IT	Collagens, biological studies RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process);				

BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(glucose crosslinking of, decrease of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Crosslinking

(reversal of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Albumins, processes

RL: PEP (Physical, engineering or chemical process); PROC (Process)
(serum, crosslinking of, reversal of; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Drug delivery systems

(tablets; thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Aging, animal

Dentifrices

Food preservation

Glycosylation

Maillard reaction

(thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT 4568-71-2P 5304-34-7P 6274-00-6P 7467-00-7P 7478-09-3P
16311-69-6P 52197-73-6P 53995-67-8P 54016-70-5P 57132-40-8P
57168-49-7P 57168-62-4P 61544-06-7P 74360-51-3P 74385-09-4P
87910-71-2P 97380-14-8P 121704-45-8P 132416-79-6P 138404-41-8P
159356-41-9P 181069-78-3P 181069-79-4P 181069-80-7P 181069-81-8P
181069-82-9P 181069-83-0P 181069-84-1P 181069-85-2P 181069-86-3P
181069-89-6P 181069-90-9P 181069-91-0P 181069-92-1P 181069-93-2P
181069-95-4P 181069-96-5P 181069-98-7P 181069-99-8P 181070-00-8P
181070-03-1P 181070-04-2P 181070-05-3P 181070-06-4P 181070-07-5P
181070-08-6P 181070-09-7P 181070-10-0P 181070-11-1P 181070-12-2P
181070-13-3P 181070-14-4P 181070-16-6P 181070-22-4P 181070-25-7P
181070-26-8P 181070-27-9P 181070-28-0P 181070-29-1P 181070-30-4P
181070-31-5P 181070-35-9P 181070-36-0P 181070-37-1P 181070-39-3P
181070-40-6P 181070-43-9P 181070-44-0P 181070-46-2P 181070-48-4P
181070-49-5P 181070-50-8P 181070-51-9P 181070-52-0P 181070-53-1P
181070-54-2P 181070-55-3P 181070-56-4P 181070-57-5P 181070-59-7P
181070-61-1P 181070-62-2P 181070-63-3P 181070-64-4P 181070-65-5P
181070-66-6P 181070-67-7P 181070-68-8P 181070-69-9P 181070-70-2P
181070-71-3P 219305-49-4P 219305-51-8P 219305-56-3P 219305-64-3P
219305-70-1P 219305-74-5P 219305-81-4P 219305-83-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT 181070-72-4P 181070-74-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT 96-32-2, Methyl bromoacetate 288-47-1, Thiazole 579-07-7,
1-Phenyl-1,2-propanedione 3581-91-7, 4,5-Dimethyl thiazole 36016-40-7,
o-Mesitylenesulfonylhydroxylamine

RL: RCT (Reactant); RACT (Reactant or reagent)

(thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; DE 2323465 1973 HCAPLUS

- (2) Anon; EP 167139 1986 HCAPLUS
- (3) Anon; EP 170037 1986
- (4) Anon; JP 1143855 1989
- (5) Anon; EP 364344 1990 HCAPLUS
- (6) Anon; JP 60184038 1990 HCAPLUS
- (7) Anon; EP 586806 1994 HCAPLUS
- (8) Anon; EP 614886 1994 HCAPLUS
- (9) Anon; WO 9411490 1994 HCAPLUS
- (10) Anon; WO 9420083 1994 HCAPLUS
- (11) Archer; J Med Chem 1979, V22, P306 HCAPLUS
- (12) Barranco; US 5366885 1994 HCAPLUS
- (13) Brownlee; Diabetes Abstract 166 1986, V42A(Suppl)
- (14) Brownlee; Science 1986, V232, P1629 HCAPLUS
- (15) Bucala; Advances in Pharmacology 1992, V23, P1 HCAPLUS
- (16) Cerami; US 4758583 1988
- (17) Chang; J Biol Chem 1985, V260, P7970 HCAPLUS
- (18) Dominianni; US 4609670 1986 HCAPLUS
- (19) Dominianni; US 4683312 1987 HCAPLUS
- (20) Dominianni; J Med Chem 1989, V32, P2301 HCAPLUS
- (21) Eble; J Biol Chem 1983, V258, P9406 HCAPLUS
- (22) Gandasegui; Heterocycles 1990, V31, P1801 HCAPLUS
- (23) Hayase; J Biol Chem 1989, V263, P3758
- (24) Kawakishi; Maillard React Chem Food Health 1994, V151, P281 HCAPLUS
- (25) Makita; J Biol Chem 1992, V267, P5133 HCAPLUS
- (26) Neurath; US 5230998 1993 HCAPLUS
- (27) Nicholls; Lab Invest 1989, V60, P486 HCAPLUS
- (28) Nordbo; J Dent Res 1979, V58, P1429
- (29) Oimomi; Agric Biol Chem 1989, V53, P1727 HCAPLUS
- (30) Pongor; Proc Natl Acad Sci USA 1984, V81, P2684 HCAPLUS
- (31) Potts; J Org Chem V41, P187 HCAPLUS
- (32) Potts; J Org Chem 1977, V42, P1648 HCAPLUS
- (33) Sell; J Biol Chem 1989, V264, P21597 HCAPLUS
- (34) Singh; Tetrahedron 1992, V48, P4545 HCAPLUS
- (35) Tamura; Synthesis 1977, V1, P1
- (36) Tsuge; Chem Lett 1982, V5, P711
- (37) Ulrich; US 5108930 1992 HCAPLUS
- (38) Ulrich; US 5262152 1993 HCAPLUS
- (39) Ulrich; Modern Aging Res 1985, V7, P83 HCAPLUS
- (40) Voller; Enzyme Immunoassays Alternative Immunoassays 1985, P77

IT 288-47-1, Thiazole

RL: RCT (Reactant); RACT (Reactant or reagent)

(thiazolium compds. for preventing and reversing the formation of
advanced glycosylation endproducts)

RN 288-47-1 HCAPLUS

CN Thiazole (6CI, 8CI, 9CI) (CA INDEX NAME)



L83 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:560531 HCAPLUS

DN 125:204548

ED Entered STN: 20 Sep 1996

TI Use of thiazolium compounds for preventing and reversing the formation of
advanced glycosylation endproducts

IN Cerami, Anthony; Ulrich, Peter C.; Wagle, Dilip R.; Hwang,
San-bao; Vasan, Sara; Egan, John J.

PA Alteon Inc., USA; The Picower Institute for Medical Research

SO PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-425

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 17, 28, 62

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9622095	A2	19960725	WO 1996-US663	19960118
	WO 9622095	A3	19970227		
	W:	AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 5656261	A	19970812	US 1995-375155	19950118
	AU 9647599	A1	19960807	AU 1996-47599	19960118
	AU 714607	B2	20000106		
	EP 808163	A2	19971126	EP 1996-903540	19960118
	EP 808163	B1	20030723		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE			
	JP 10512864	T2	19981208	JP 1996-522379	19960118
	US 5853703	A	19981229	US 1996-588249	19960118
	BR 9607598	A	19991130	BR 1996-7598	19960118
	AT 245420	E	20030815	AT 1996-903540	19960118
	FI 9703031	A	19970915	FI 1997-3031	19970717
	NO 9703308	A	19970918	NO 1997-3308	19970717
	US 38330	E	20031125	US 1999-373345	19990812
PRAI	US 1995-375155	A	19950118		
	US 1996-588249	A	19960118		
	US 1995-473104	B2	19950607		
	US 1995-473184	A	19950607		
	WO 1996-US663	W	19960118		
OS	MARPAT 125:204548				
AB	Compns. and methods for inhibiting and reversing nonenzymic crosslinking (protein aging) are disclosed. Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins (such as thiazolium salts), and which addnl. reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving α -dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymic crosslinking is also disclosed. Thiazole 850 mg, Me bromoacetate 1.52 mg, and absolute ethanol 50 mL were refluxed for 2 h, then cooled and the salt separated and recrystd. to obtain 3-(2-methoxy-2-oxoethyl)-thiazolium bromide (I). A lotion contained I 1.0, ethanol 200.0, PEG-400 300.0, hydroxypropyl cellulose 5.0 mg, and propylene glycol q.s. 1.0 g.				
ST	thiazolium deriv advanced glycosylation endproduct prevention; lotion thiazolium bromide deriv protein aging				
IT	Proteins, biological studies				
	RL: BSU (Biological study, unclassified); BIOL (Biological study) (aging ; use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)				
IT	Dentifrices				
	Mouthwashes				
	(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)				
IT	Antibodies				
	RL: BSU (Biological study, unclassified); BIOL (Biological study)				

(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Glycoproteins, specific or class

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(AGE (advanced glycosylation end product), use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Pharmaceutical dosage forms

(lotions, use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT Pharmaceutical dosage forms

(tablets, use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT 4568-71-2P 5304-34-7P 6274-00-6P 7467-00-7P 7478-09-3P
 16311-69-6P 52197-73-6P 53995-67-8P 54016-70-5P 57132-40-8P
 57168-49-7P 57168-62-4P 61544-06-7P 74360-51-3P 74385-09-4P
 87910-71-2P 97380-14-8P 121704-45-8P 132416-79-6P 138404-41-8P
 159356-41-9P 181069-78-3P 181069-79-4P 181069-80-7P 181069-81-8P
 181069-82-9P 181069-83-0P 181069-84-1P 181069-85-2P 181069-86-3P
 181069-89-6P 181069-90-9P 181069-91-0P 181069-92-1P 181069-93-2P
 181069-95-4P 181069-96-5P 181069-98-7P 181069-99-8P 181070-00-8P
 181070-03-1P 181070-04-2P 181070-05-3P 181070-06-4P 181070-07-5P
 181070-08-6P 181070-09-7P 181070-10-0P 181070-11-1P 181070-12-2P
 181070-13-3P 181070-14-4P 181070-15-5P 181070-16-6P 181070-18-8P
 181070-22-4P 181070-24-6P 181070-25-7P 181070-26-8P 181070-27-9P
 181070-28-0P 181070-29-1P 181070-30-4P 181070-31-5P 181070-33-7P
 181070-35-9P 181070-36-0P 181070-37-1P 181070-38-2P 181070-39-3P
 181070-40-6P 181070-41-7P 181070-43-9P 181070-44-0P 181070-46-2P
 181070-48-4P 181070-49-5P 181070-50-8P 181070-51-9P 181070-52-0P
 181070-53-1P 181070-54-2P 181070-55-3P 181070-56-4P 181070-57-5P
 181070-58-6P 181070-59-7P 181070-60-0P 181070-61-1P 181070-62-2P
 181070-63-3P 181070-64-4P 181070-65-5P 181070-66-6P 181070-67-7P
 181070-68-8P 181070-69-9P 181070-70-2P 181070-71-3P 181070-72-4P
 181070-74-6P 181147-74-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT 96-32-2, Methyl bromoacetate 288-47-1, Thiazole 3581-91-7, 4,5-Dimethylthiazole 58042-39-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

IT 288-47-1, Thiazole

RL: RCT (Reactant); RACT (Reactant or reagent)

(use of thiazolium compds. for preventing and reversing the formation of advanced glycosylation endproducts)

RN 288-47-1 HCAPLUS

CN Thiazole (6CI, 8CI, 9CI) (CA INDEX NAME)

